Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could dropping aspirin after a heart attack be safer?

NCT ID NCT07257198

Disease control Sponsor: Montreal Heart Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking only the blood thinner ticagrelor (instead of the usual combination of ticagrelor plus aspirin) can reduce bleeding after a heart attack. It involves 2,570 adults who had a heart attack but did not receive stents or bypass surgery. Participants will take either ticagrelor plus a placebo or ticagrelor plus aspirin for 12 months, and researchers will compare bleeding events and major heart problems between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ticagrelor (a blood thinner) plus a placebo, compared to ticagrelor plus aspirin
What this could lead to
If successful, this could show that using only ticagrelor after a heart attack lowers bleeding risk while still preventing future heart problems, leading to a safer treatment option.
What could go wrong
This is a large Phase 3 trial, but it only includes patients who did not receive stents or bypass surgery, so results may not apply to everyone. There is still a risk that ticagrelor alone may not prevent heart attacks or strokes as well as the standard combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 2,570 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Age ≥18 years; * Hospitalized for type 1 MI, according to the 4th Universal Definition of MI; * Coronary angiogram performed; * Planned for medical management alone, without revascularization; * Willingness to participate and to attend study visits; * Expected life expectancy ≥12 months. Exclusion criteria: * Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI; * Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel; * Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.); * Confirmed or suspected spontaneous coronary artery dissection; * Concomitant indication for chronic oral anticoagulant; * Concomitant non-coronary indication for dual antiplatelet therapy; * Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician; * Previous hospitalization for MI, PCI, or CABG within 12 months; * Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor; * Unsuitability for either randomization treatment, based on the judgement of the treating physician

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute subendocardial myocardial infarction Hemorrhage myocardial infarction Non-ST Elevated Myocardial Infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction Nstemi - non-ST segment elevation mi Stemi (ST elevation mi)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Montreal Heart Institute

    RECRUITING

    Montreal, Quebec, H1Y2P3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.